Improvements in Renal Function with Selinexor in Relapsed/Refractory Multiple Myeloma: Post-hoc Analyses from the STORM Study

Abstract

There is an unmet need for effective therapies in patients (pts) with adverse prognostic factors such as renal impairment, a common complication of multiple myeloma (MM). Selinexor (SEL), a novel, oral selective inhibitor of nuclear export (SINE) blocks XPO1, forcing nuclear activation of tumor suppressor proteins. In the STORM study, SEL plus low dose dexamethasone (SEL-DEX) induced an overall response rate (ORR) of 26.2% in pts with penta-exposed, triple-class refractory MM. Side effects were generally reversible without evidence of major organ toxicities.